Kwak Brenda R, Mulhaupt Flore, Mach François
Division of Cardiology, University Hospital, Foundation for Medical Research, Faculty of Medicine, 64 Avenue de la Roseraie, 1211 Geneva 4, Switzerland.
Autoimmun Rev. 2003 Oct;2(6):332-8. doi: 10.1016/s1568-9972(03)00049-1.
Large clinical trials have demonstrated that HMG-CoA reductase inhibitors or 'statins' greatly reduce cardiovascular-related morbidity and mortality. The beneficial effects of statins were first assumed to result from their ability to reduce cholesterol synthesis and improve serum lipid profiles. In recent years, however, numerous pleiotropic effects of statins on atherosclerotic lesions have been described. In this review, we summarize the actions of statins on different aspects of atherosclerotic plaque development. These include endothelial dysfunction, leukocyte recruitment and inflammation, smooth muscle cell activation/proliferation, and finally plaque rupture and thrombosis.
大型临床试验表明,HMG-CoA还原酶抑制剂或“他汀类药物”可显著降低心血管相关的发病率和死亡率。他汀类药物的有益作用最初被认为是由于它们能够减少胆固醇合成并改善血脂谱。然而,近年来,他汀类药物对动脉粥样硬化病变的多种作用已被描述。在本综述中,我们总结了他汀类药物在动脉粥样硬化斑块发展不同方面的作用。这些作用包括内皮功能障碍、白细胞募集和炎症、平滑肌细胞活化/增殖,以及最终的斑块破裂和血栓形成。